

Company News

November 7, 2000

Ono and Schering-Plough Signed a License Agreement For Leukotriene Antagonist Pranlukast Hydrate

Ono Pharmaceutical Co., Ltd. has signed a License Agreement with Schering-Plough Corporation of Kenilworth, New Jersey, USA, to develop and market in Latin America Ono's pranlukast hydrate (Japanese trademarks: Onon^(R) Capsule and Onon^(R) Dry Syrup). Under the terms of the agreement, Ono will receive an up-front signing fee and milestone payments on product sales. Schering-Plough will receive an exclusive license to the products, which will be supplied by Ono. Financial terms of the agreement are not being disclosed.

Onon^(R) Capsule was the first leukotriene antagonist to be approved in Japan and was launched in Japan in 1995 for the treatment of bronchial asthma. Additional launches were made in Japan in January 2000 for the treatment of allergic rhinitis (Onon^(R) Capsule) and of pediatric bronchial asthma (Onon^(R) Dry Syrup).